Home / Market News / $BRKR

$BRKR news and market catalysts

The 17 most recent market catalysts affecting $BRKR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

17 catalysts 3 high impact 6 bullish 4 bearish Medical Devices
Nov 16, 2026 Corporate Catalyst Neutral Impact 55
Bruker Announces Appointment of Dr. Eicke Latz to Board of Directors
Bruker Corporation announced the future appointment of Dr. Eicke Latz to its Board of Directors, effective January 1, 2027. This move is significant as Dr. Latz brings specialized …
Nov 12, 2026 Corporate Catalyst Neutral Impact 55
Biognosys Group Launches Industrialized Discovery Proteomics Service
Biognosys Group, a fully owned affiliate of Bruker Corporation, has launched its 'Industrialized Discovery' service. This new offering aims to significantly improve the scalability…
Nov 10, 2026 Corporate Catalyst Neutral Impact 55
TOFWERK Joins SubFAB Labs Initiative for Semiconductor Process Monitoring
TOFWERK, a subsidiary of Bruker Corporation, has joined the SubFAB Labs initiative. This collaboration focuses on applying TOFWERK's mass spectrometry technology to monitor by-prod…
Nov 4, 2026 Corporate Catalyst Neutral Impact 90
Bruker Reports Third Quarter 2026 Financial Results
Bruker Corporation released its Q3 2026 earnings report, a critical event for any publicly traded company. This filing provides investors with a detailed look into the company's fi…
Oct 14, 2026 Corporate Catalyst Bearish Impact 65
JP Morgan Downgrades Bruker to Neutral, Announces $60 Price Target
JP Morgan analyst Casey Woodring downgraded Bruker (BRKR) from Overweight to Neutral and announced a $60 price target. This analyst downgrade is significant because it reflects a c…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Bruker, Raises Price Target to $70
Barclays analyst Luke Sergott has maintained an 'Overweight' rating on Bruker (BRKR) and significantly raised the price target from $58 to $70. This action signals increased confid…
Sep 29, 2026 Corporate Catalyst Bullish Impact 65
Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $80
Leerink Partners analyst Puneet Souda has raised the price target for Bruker (BRKR) from $60 to $80 while maintaining an Outperform rating. This is a positive development for Bruke…
Sep 21, 2026 Corporate Catalyst Bullish Impact 55
Bruker Wins Major UC Berkeley Order For Advanced Research Systems
Bruker Corporation announced a significant multi-system order from the University of California, Berkeley, specifically for high-field Nuclear Magnetic Resonance (NMR) instrumentat…
Sep 4, 2026 Corporate Catalyst Bullish Impact 65
Bruker, Luvata Team Up To Boost Superconductor Supply For Fusion Power Projects
Bruker's Energy & Supercon Technologies (BEST) segment is partnering with Luvata Materials & Solutions to address the increasing demand for superconductors in fusion power projects…
Aug 11, 2026 Corporate Catalyst Neutral Impact 65
Bruker Announces Expanded Strategic Collaboration With And Minority Investment In Self-Driving Labs Firm Atinary Technologies; Terms Not Disclosed
This announcement represents a strategic expansion for Bruker into the rapidly growing field of AI-driven lab automation, which could lead to enhanced product development and marke…
Aug 10, 2026 Corporate Catalyst Bullish Impact 75
Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.
This headline indicates a significant strategic move by Bruker, expanding its footprint in the rapidly evolving post-genomic and drug discovery sectors through microphysiological s…
Aug 10, 2026 Corporate Catalyst Neutral Impact 65
Bruker Announces Majority Investment In Organ-On-A-Chip Developer MIMETAS, Expanding Into Microphysiological Systems For Drug Discovery; Terms Not Disclosed
Bruker's majority investment in MIMETAS is a strategic move to expand its footprint in the rapidly evolving microphysiological systems (MPS) market, which is crucial for drug disco…
Aug 5, 2026 Corporate Catalyst Bearish Impact 55
Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53
Citigroup analyst Brendan Digan maintained a 'Neutral' rating on Bruker (BRKR) but lowered the price target from $60 to $53. This action indicates a revised outlook on the company'…
Aug 4, 2026 Corporate Catalyst Bearish Impact 85
Bruker shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for Bruker (BRKR). The combination of 'mixed' Q2 results, implying some underperformance or inconsistency, and a 'cut' to …
Aug 4, 2026 Corporate Catalyst Bearish Impact 75
Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B Est
Bruker (BRKR) has affirmed its FY2026 adjusted EPS guidance, which is a positive signal for its profitability management. However, the company simultaneously lowered its FY2026 sal…
Aug 4, 2026 Corporate Catalyst Bullish Impact 85
Bruker Q2 Adj. EPS $0.49 Beats $0.39 Estimate, Sales $838.500M Miss $853.543M Estimate
Bruker's Q2 earnings report presents a mixed picture for investors. The significant beat on adjusted EPS, exceeding estimates by over 25% and showing strong year-over-year growth, …
Jul 15, 2026 Corporate Catalyst Neutral Impact 55
Bruker Acquires The DISQVER Clinical Metagenomics Platform From Noscendo; Financial Terms Not Disclosed
Bruker has acquired the DISQVER clinical metagenomics platform from Noscendo. This acquisition is significant because it expands Bruker's infection detection capabilities by integr…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.